TOTAL Therapy 7: high response rates in high risk NDMM to daratumumab
The TOTAL Therapy (TT) approach has significantly improved the outcome of multiple myeloma (MM) by combining new drugs with a…
The TOTAL Therapy (TT) approach has significantly improved the outcome of multiple myeloma (MM) by combining new drugs with a…
On February 11, 2025, the U.S. Food and Drug Administration (FDA) granted approval to brentuximab vedotin (BV) combined with lenalidomide…
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares his excitement for the upcoming…
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, highlights the need to address inequality and inequity in access to CAR T-cell therapy across Europe.…
In this video, Anne Spanjaart, MD, Amsterdam University Medical Center, Amsterdam, Netherlands, and Elise Pennings, MD, Amsterdam University Medical Center & Erasmus School of Health…
This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and…
Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the incidence of cardiac complications after CAR T-cell therapy, stating that…
Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, shares updates on the recent approval of CAR-T therapy for patients with chronic lymphocytic…
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, comments on the treatment options available in the UK for newly…
In this video, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, shares updated results from the FELIX trial (NCT04404660), which is evaluating the…
Jointly organized by the EHA and EBMT, the 7th European CAR T-cell Meeting is taking place on February 6-8, 2025, in Strasbourg, France, and online,…